CoLucid Pharmaceuticals, Inc. 4
4 · CoLucid Pharmaceuticals, Inc. · Filed Jan 4, 2017
Insider Transaction Report
Form 4
Dallas Matthew D
Chief Financial Officer
Transactions
- Sale
Common Stock
2017-01-03$36.25/sh−1,473$53,396→ 40,128 total
Footnotes (1)
- [F1]Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.